Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7426 - 7450 of 8179 in total
Alflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With T790M).
Investigational
Matched Description: … Alflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in …
Fasoracetam is under investigation in clinical trial NCT03609619 (PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without Mglur Mutations).
Investigational
Matched Description: … Fasoracetam is under investigation in clinical trial NCT03609619 (PART B: Efficacy and Safety of AEVI …
Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual Β-Cell Function).
Investigational
Matched Description: … Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset …
Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
Investigational
Matched Description: … Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination …
Pelacarsen is under investigation in clinical trial NCT03070782 (Phase 2 Study of ISIS 681257 (Akcea-apo(a)-lrx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease).
Investigational
Matched Description: … Pelacarsen is under investigation in clinical trial NCT03070782 (Phase 2 Study of ISIS 681257 (Akcea-apo …
Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).
Investigational
Matched Description: … Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l …
Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).
Investigational
Matched Description: … Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of
TAK-611, formerly known as SHP611, is a recombinant human arylsulfatase A. First developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy.
Investigational
Matched Description: … First developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy …
KP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal antibody binding terminus binder) connected by a linker chain.
Investigational
Matched Description: … KP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal …
Rademikibart is under investigation in clinical trial NCT04773678 (Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation).
Investigational
Matched Description: … Rademikibart is under investigation in clinical trial NCT04773678 (Efficacy and Safety of CBP-201 in …
CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure. It is a unique treatment modality that...
Investigational
Matched Description: … CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. ... It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient …
Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for...
Investigational
Matched Description: … antibody, for the potential treatment of allergic conditions. ... It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE …
Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment...
Investigational
Matched Description: … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients ... It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both …
Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication. CDCs target multiple cytokine pathways associated with poor outcomes (e.g. TNFa, IFN-y, IL-1B, and...
Investigational
Matched Description: … their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of ... The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function …
SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy. This study was designed to evaluate whether avosentan influences the pharmacokinetics of steroid oral contraceptives.
Investigational
Matched Description: … This study was designed to evaluate whether avosentan influences the pharmacokinetics of steroid oral …
Bombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers).
Investigational
Matched Description: … Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of
Pimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen).
Investigational
Matched Description: … Pimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone …
ARO-ANG3 is a subcutaneously administered RNA interference (RNAi)-based investigational medicine targeting angiopoietin-like protein 3 (ANGPTL3). It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia (HoFH).
Investigational
Matched Description: … It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia …
CER-001 is a negatively charged lipoprotein particle comprising human recombinant apolipoprotein A-I and two phospholipids: sphingomyelin and dipalmitoylphosphatidylglycerol. It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies.
Investigational
Matched Description: … [L48290] It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies …
AVR-RD-04 is an investigational gene therapy for cystinosis. It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin.
Investigational
Matched Description: … It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting …
BGT-DTDS is an investigational gene therapy comprising an adeno-associated viral vector type 2 (AAV2) encoding the human SLC6A3 gene. It is under investigation for the treatment of dopamine transporter deficiency syndrome (DTDS).
Investigational
Matched Description: … It is under investigation for the treatment of dopamine transporter deficiency syndrome (DTDS). …
VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.
Investigational
Matched Description: … VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases …
MX6 is adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat...
Investigational
Matched Description: … and therefore may be used for the treatment of cancer, including advanced cancer. ... MX6 is adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells …
Human olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) reside in an accessible location of the nasal cavity and have properties of multipotency and high proliferation, which contributes to high potential for regenerative medicine. In humans, OM-MSCs are derived from the olfactory mucosa which is collected in vivo through rhinoscopy techniques and...
Investigational
Matched Description: … Human olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) reside in an accessible location of the ... nasal cavity and have properties of multipotency and high proliferation, which contributes to high potential …
CoviGlobulin, a rabbit polyclonal antibody, was specifically designed as a potential therapy for COVID-19. Rabbit polyclonal antibodies are derived from the rabbit, a common animal host for polyclonal production. The antibodies themselves are produced in response to an immunogen and derived from antibody-producing plasma cells that were once B-cell clones....
Investigational
Matched Description: … Different antibodies have different mechanisms of action depending on their target. ... Current applications of antibodies include, but are not limited to, targeting cancer, inflammatory diseases …
Displaying drugs 7426 - 7450 of 8179 in total